Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares are down during Thursday’s premarket session as the company reported its fourth-quarter and full-year 2025 financial results.
Over the last year, the company’s stock has plunged from $106.86 to $18.96, due to patient deaths, FDA clinical hold, trial setbacks, and shipment pause.
Earnings Snapshot
On Wednesday, Sarepta Therapeutics reported an adjusted loss of $3.58 per share, missing the Wall Street estimate loss of $1.31. Sales reached $442.93 million, beating the consensus of $391.92 million.
The sales fell 33% year over year, primarily reflecting $273.8 million less in net product revenue of Elevidys as a result of lower volume following the company’s decision to suspend shipments of Elevidys to non-ambulatory patients in the U.S. in June 2025.
“Following a tumultuous 2025, we entered 2026 from a position of strength… In 2025, we streamlined our operations, delivered strong revenue, and ended the year with nearly $1.0 billion in cash, as we anticipate remaining profitable and cash‑flow positive in 2026. ELEVIDYS has emerged from a challenging year with a clear label, traditional approval for ambulatory patients, and a plan intended to put us on a potential pathway back to serving the non‑ambulatory community…,” said Doug Ingram, CEO, Sarepta Therapeutics.
Management Transition
In an SEC filing on Wednesday, Douglas Ingram shared his plan to retire as Chief Executive Officer by the end of 2026 or upon the appointment of his replacement. The company has commenced a search.
Analyst View
William Blair on Thursday wrote “…the Elevidys weakness in the fourth quarter is not an outlier but was an early signal of a materially weaker Elevidys trajectory in 2026, with Elevidys revenues likely to dip well below the $500 million/year floor that was reiterated in January.”
Although the company has guided for stable PMO revenue in 2026, given the recent failure of the ESSENCE trial, analyst Sami Corwin is hesitant due to concerns that Vyondys 53 and Amondys 45 may lose their marketing authorization.
The analyst also highlights that Dyne Therapeutics Inc. (NASDAQ:DYN) intends to seek the accelerated approval of its Exon 51 skipper in the second quarter, which could further impact Sarepta’s top line.
Last, while investors have polarized views of CEO Doug Ingram, uncertainty about his successor could cause additional stock volatility in the near term. Taken together, William Blair views the stock’s near-term upside potential as limited and reiterates its rating of Market Perform.
Technical Analysis
Currently, the stock is trading 3.5% below its 20-day simple moving average (SMA) and 9.8% below its 100-day SMA, indicating a bearish trend in the short to medium term. Over the past 12 months, shares have decreased significantly and are currently positioned closer to their 52-week lows than highs.
The RSI is at 50.00, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is at -0.10, below its signal line at -0.05, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in market sentiment.
- Key Resistance: $20.00
- Key Support: $15.00
SRPT Price Action: Sarepta Therapeutics shares were down 3.53% at $18.30 during premarket trading on Thursday, according to Benzinga Pro data.
Photo via Shutterstock